IL-14 Inhibitors
IL-14 inhibitors encompass a spectrum of chemicals that primarily act through indirect modulation of signaling pathways associated with interleukin-14 (IL-14). The limited availability of direct inhibitors prompts exploration of compounds targeting key cellular pathways intricately linked to IL-14 expression and function. Among these, SP600125 and SP463 serve as JNK inhibitors, influencing the MAPK pathway. As JNK is involved in cellular responses, their inhibition can indirectly alter IL-14 expression. LY294002 and Wortmannin, both PI3K inhibitors impacting the PI3K/Akt pathway, have the potential to indirectly modulate IL-14 by altering downstream signaling cascades associated with cellular survival and growth.
PD98059, U0126, and VX-745 act as inhibitors of the MAPK pathway, specifically targeting MEK and p38 MAPK, respectively. By suppressing these components, these inhibitors may indirectly influence IL-14 expression and function through downstream signaling events. Ruxolitinib, a JAK1/2 inhibitor, impacts the JAK/STAT pathway, suggesting a potential indirect modulation of IL-14 signaling, given the involvement of JAK/STAT in IL-14 regulation. Celecoxib, a COX-2 inhibitor affecting the arachidonic acid pathway, may influence IL-14 through the modulation of prostaglandin synthesis and related inflammatory signaling pathways. LY2228820, AZD5363, and VX-745 target MET, AKT, and p38 MAPK, respectively, providing avenues for indirect modulation of IL-14 expression through their effects on relevant downstream signaling pathways.
SEE ALSO...
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
SP600125 | 129-56-6 | sc-200635 sc-200635A | 10 mg 50 mg | $40.00 $150.00 | 257 | |
JNK inhibitor influencing the MAPK pathway. JNK is known to interact with signaling cascades involved in cellular responses, and its inhibition may indirectly modulate IL-14 expression and function. | ||||||
LY 294002 | 154447-36-6 | sc-201426 sc-201426A | 5 mg 25 mg | $123.00 $400.00 | 148 | |
PI3K inhibitor affecting the PI3K/Akt pathway. This pathway is intricately linked to cellular survival and growth. Inhibition of PI3K can potentially impact IL-14 through downstream signaling pathways, altering its expression and function indirectly. | ||||||
PD 98059 | 167869-21-8 | sc-3532 sc-3532A | 1 mg 5 mg | $40.00 $92.00 | 212 | |
MEK inhibitor targeting the MAPK pathway. By suppressing MEK, this chemical modulates downstream signaling events that may indirectly influence IL-14 expression and function in relevant cellular contexts. | ||||||
PD 169316 | 152121-53-4 | sc-204168 sc-204168A sc-204168B sc-204168C | 1 mg 5 mg 10 mg 25 mg | $88.00 $156.00 $281.00 $461.00 | 3 | |
p38 MAPK inhibitor impacting the MAPK pathway. p38 MAPK is involved in various cellular processes, and its inhibition can potentially alter IL-14 expression indirectly through downstream effects on related pathways. | ||||||
Wortmannin | 19545-26-7 | sc-3505 sc-3505A sc-3505B | 1 mg 5 mg 20 mg | $67.00 $223.00 $425.00 | 97 | |
PI3K inhibitor, similar to LY294002, affecting the PI3K/Akt pathway. By inhibiting PI3K, Wortmannin can indirectly modulate IL-14 expression and function through the intricate network of signaling cascades linked to PI3K/Akt. | ||||||
Ruxolitinib | 941678-49-5 | sc-364729 sc-364729A sc-364729A-CW | 5 mg 25 mg 25 mg | $251.00 $500.00 $547.00 | 16 | |
JAK1/2 inhibitor impacting the JAK/STAT pathway. IL-14 signaling can be influenced by the JAK/STAT pathway, and the inhibition of JAKs can potentially modulate IL-14 expression indirectly through altered downstream events in this pathway. | ||||||
LY2228820 | 862507-23-1 | sc-364525 | 5 mg | $191.00 | 1 | |
MET inhibitor impacting the MET receptor pathway. MET signaling is involved in various cellular processes, and its inhibition may indirectly modulate IL-14 expression and function through downstream effects on related pathways. | ||||||
AZD5363 | 1143532-39-1 | sc-503190 | 5 mg | $309.00 | ||
AKT inhibitor affecting the PI3K/Akt pathway. Since AKT is a key player in the PI3K/Akt pathway, its inhibition by AZD5363 may indirectly impact IL-14 expression and function through altered downstream signaling events in this pathway. | ||||||
VX 745 | 209410-46-8 | sc-361401 sc-361401A | 10 mg 50 mg | $183.00 $842.00 | 4 | |
p38 MAPK inhibitor influencing the MAPK pathway. Similar to SB203580, VX-745 modulates p38 MAPK, potentially affecting IL-14 indirectly through the modulation of downstream signaling events within the MAPK pathway. | ||||||